The first participant enrolled on Friday in the PLATINUM (Placebo-controlled randomized trial of tecovirimat in nonhospitalised monkeypox patients) trial, building off animal model successes that led to FDA and UK approvals, and follows the NIH’s National Institute of Allergy and Infectious Diseases announcement that it’s launching a similar trial in the US next week.
MiroBio was spun out of the University of Oxford in 2019 to develop a new class of medicines, called immune checkpoint agonists, to treat autoimmune diseases by restoring balance to the immune system. The company was co-founded by OSE and Tim Funnell, OSE’s entrepreneur in residence at the time, and Samsara BioCapital, working closely with MiroBio’s scientific founders – Simon Davis, professor of Molecular Immunology, MRC Weatherall Institute of Molecular Medicine, and Richard Cornall, Nuffield professor of Clinical Medicine.
PALO ALTO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced that a team led by researchers at University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) in the U.K. to conduct a feasibility trial to investigate whether anti-tumor necrosis factor (TNF) therapy, administered at the time of surgery, can reduce or prevent post operative delirium/cognitive deficit (“post-operative delirium”).
The novel coronavirus vaccine has been developed at Caltech and The University of Oxford. Funding of up to $30 million will support vaccine design, its development through Phase I trials and regulatory activities.
The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has...
CINCINNATI, May 31, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address...
Novavax is participating in a stage of the COVID-19 Vaccine Schedule Combinations (Com-COV) program initiated by the University of Oxford and supported by the UK Vaccine Taskforce and the National Institute for Health and Care Research. Novavax' protein-based COVID-19 vaccine, NVX-CoV2373, is one of two COVID-19 vaccines that will be studied as a third dose booster in adolescents aged 12 through 15 years to evaluate the potential use of vaccines from different manufacturers to achieve immune protection against COVID-19.
The study achieved the primary endpoint of reduction in nodule hardness at 12 months and secondary endpoint of reduction in nodule size at multiple time points including 12 monthsThe treatment arm...
OxDX has raised £2.6m in pre-seed funding for its AI powered diagnostic technology. The method can recognise and identify specific species and strains of viruses, bacteria and other pathogens within a sample in seconds.
Feb 15 (Reuters) - Oxford University scientists said on Tuesday they would evaluate the effects of new coronavirus variants on pregnant women and newborns, as well as COVID-19 vaccination effects on complications during pregnancy and after birth.